Comments on the discordant recommendations for the use of symptomatic slow-acting drugs in knee osteoarthritis |
| |
| Authors: | Jean-Yves Reginster Cyrus Cooper Marc Hochberg Jean-Pierre Pelletier René Rizzoli John Kanis |
| |
| Affiliation: | 1. Support Unit in Epidemiology and Biostatistics, Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium;2. MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK;3. NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, UK;4. Division of Rheumatology &5. Clinical Immunology, Department of Medicine, University of Maryland School of Medicine, MD, USA;6. Geriatric Research, Education and Clinical Center, Maryland VA Health Care System, Baltimore, MD, USA;7. Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, Quebec, Canada;8. Service of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland;9. WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK |
| |
| Abstract: | Despite the near concurrent publication by influential scientific organizations, there are important differences in interpretation of the evidence base and the conclusions derived from the recent Osteoarthritis Research Society International (OARSI) guidelines for the management of knee osteoarthritis, the American College of Rheumatology (ACR) guidelines (concerning also hip and hand osteoarthritis) and the algorithm recommendations by the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). This is particularly evident for the drug class of symptomatic slow-acting drugs in osteoarthritis. In this paper, we highlight these differences and try to understand where they derive from, proposing an evidence-based interpretation. |
| |
| Keywords: | Chondroitin Glucosamine Hyaluronic acid Osteoarthritis Symptomatic slow-acting drugs in osteoarthritis |
|
|
